Chris Viehbacher, Biogen CEO (Suzanne Kreiter/The Boston Globe via Getty Images)
Biogen's $7.3B deal for Reata followed a bidding war with mysterious 'Party A'
Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals — its first major deal in more than four years — came after a showdown with another potential buyer that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.